Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles.
about
Autonomic, locomotor and cardiac abnormalities in a mouse model of muscular dystrophy: targeting the renin-angiotensin systemChronic oral administration of Ang-(1-7) improves skeletal muscle, autonomic and locomotor phenotypes in muscular dystrophy.ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis.Endotoxin induces fibrosis in vascular endothelial cells through a mechanism dependent on transient receptor protein melastatin 7 activity.Angiotensin-dependent autonomic dysregulation precedes dilated cardiomyopathy in a mouse model of muscular dystrophy.Angiotensin-(1-7) attenuates disuse skeletal muscle atrophy in mice via its receptor, MasThe link between stress disorders and autonomic dysfunction in muscular dystrophyRole of proteoglycans in the regulation of the skeletal muscle fibrotic response.Cardiac and respiratory dysfunction in Duchenne muscular dystrophy and the role of second messengers.Therapeutic approaches to skeletal muscle repair and healing.Cellular and molecular actions of CCN2/CTGF and its role under physiological and pathological conditions.Renin-angiotensin system: an old player with novel functions in skeletal muscle.SMAD3 and SP1/SP3 Transcription Factors Collaborate to Regulate Connective Tissue Growth Factor Gene Expression in Myoblasts in Response to Transforming Growth Factor β.Angiotensin-(1-7) decreases skeletal muscle atrophy induced by angiotensin II through a Mas receptor-dependent mechanism.Transforming growth factor type beta 1 increases the expression of angiotensin II receptor type 2 by a SMAD- and p38 MAPK-dependent mechanism in skeletal muscle.Andrographolide attenuates skeletal muscle dystrophy in mdx mice and increases efficiency of cell therapy by reducing fibrosis.High Fat Diet-Induced Skeletal Muscle Wasting Is Decreased by Mesenchymal Stem Cells Administration: Implications on Oxidative Stress, Ubiquitin Proteasome Pathway Activation, and Myonuclear Apoptosis.Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular DystrophyEndotoxin-induced endothelial fibrosis is dependent on expression of transforming growth factors β1 and β2.Oxidative stress mediates the conversion of endothelial cells into myofibroblasts via a TGF-β1 and TGF-β2-dependent pathway.The Ang-(1-7)/Mas-1 axis attenuates the expression and signalling of TGF-β1 induced by AngII in mouse skeletal muscle.Blockade of Bradykinin receptors worsens the dystrophic phenotype of mdx mice: differential effects for B1 and B2 receptors.The pro-fibrotic connective tissue growth factor (CTGF/CCN2) correlates with the number of necrotic-regenerative foci in dystrophic muscle.Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2).Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy.The angiotensin-(1-7)/Mas axis reduces myonuclear apoptosis during recovery from angiotensin II-induced skeletal muscle atrophy in mice.Expression of the Mas receptor is upregulated in skeletal muscle wasting.
P2860
Q26996208-E219C0BC-4A67-4FF5-B1FA-0A6782090681Q35053205-135840C8-3AC7-48E5-A3C9-2ACF9DF60970Q35138448-CA1BD6D5-9118-4C3A-9FAD-F6489D976747Q35141755-1B645C34-31FC-4743-BC8A-A4E7CD4CFE99Q35861077-1F881A39-F05C-4737-A949-EDB5F1A091E6Q36856035-E328B67B-AC53-4021-AE6B-0B487B4EE89EQ37526343-147331C7-3814-4770-8ED8-6E1C0897F53BQ38096495-37BF4EBE-A49C-4F59-8FAE-84F9DC6DAC9FQ38103213-20C1A49E-69E8-4F2D-8302-871335F96BD7Q38225126-7095B44D-664F-4DBD-800B-C740C8A33B81Q38258015-FF340F19-D864-45A9-BE7B-ACC950D41D4AQ38375202-B10BDDCB-87DC-4914-BC24-90EBC372860DQ38905039-B60DC76E-A5E4-4680-8040-DB39E7FB1000Q38956473-7A137FB5-D9AC-4C6A-A660-F6660B92BD03Q39185363-86FB84C0-B599-4DD1-9EBB-E3FD4ECBAC68Q39629598-5DA3396B-C106-436F-A669-66E77542E2F3Q41479479-94D8A032-53C1-4E43-A0C1-D8CA77801E96Q42836794-442A78E2-DB0B-4BE9-BBAB-B31FBC9E707EQ42932656-33445241-FD3C-4C47-B750-07F97D4B382FQ46860194-CF9B61BC-90F5-4B7C-B407-4022F396F936Q46924901-029AB43E-00B8-4EB9-B9BC-3D4D90779159Q47776900-F566D71C-75AA-435B-9CF6-8524E5B25401Q48100107-34C625CF-0D3D-4442-A499-96738B4E3A71Q50994524-64B40B5B-7CAC-410E-B69A-C3699952600AQ52564618-69F931A4-05DA-4931-8E5E-201BA81D8300Q54189352-B206165C-0D06-4919-8C62-0C08B23D7709Q54192199-1455FCF1-07A4-4163-84AD-35986EE328ED
P2860
Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Angiotensin II receptor type 1 ...... d dystrophic skeletal muscles.
@en
Angiotensin II receptor type 1 ...... d dystrophic skeletal muscles.
@nl
type
label
Angiotensin II receptor type 1 ...... d dystrophic skeletal muscles.
@en
Angiotensin II receptor type 1 ...... d dystrophic skeletal muscles.
@nl
prefLabel
Angiotensin II receptor type 1 ...... d dystrophic skeletal muscles.
@en
Angiotensin II receptor type 1 ...... d dystrophic skeletal muscles.
@nl
P2093
P2860
P1476
Angiotensin II receptor type 1 ...... nd dystrophic skeletal muscles
@en
P2093
Claudio Cabello-Verrugio
Daniel Cabrera
María Gabriela Morales
P2860
P304
P356
10.1111/J.1582-4934.2011.01354.X
P577
2012-04-01T00:00:00Z